Malaria drug may help treat dementia
Washington: A new study has revealed that various drugs already on the market to treat malaria, angina pectoris or heart rhythm disturbances could also be used in treating a specific form of frontotemporal dementia.
Frontotemporal dementia is caused by the breakdown of nerve cells in the frontal and temporal region of the brain (fronto-temporal lobe), which leads to, among other symptoms, a change in personality and behaviour.
Some forms of frontotemporal dementia are caused by a genetically determined reduction of a hormone-like growth factor progranulin.
Anja Capell and Prof. Christian Haass have now shown that these drugs could increase the production of progranulin.
As for almost every other gene, there are also two copies of the progranulin gene in the cell. In patients with progranulin dependent frontotemporal dementia, one of the two copies is defective, leading to a 50 percent reduction in progranulin levels.
To rescue the lack of progranulin, the Munich researchers tested various substances for their ability to stimulate the remaining progranulin production and identified a drug called bafilomycin (BafA1).
They then examined the molecular mechanism underlying the impact of BafA1 on progranulin more closely. Growth factors such as progranulin are produced in cellular membrane inclusions, known as vesicles.
BafA1 has an alkalising effect on these vesicles. After administration of BafA1 the interior of the vesicles is less acidic – and this increases the production of progranulin.
This observation encouraged the researchers to investigate further alkalising substances for their ability to raise progranulin levels.
Among the substances that passed the test were three drugs that are already on the market to treat various diseases: a medication for angina pectoris (bepridil), one for heart rhythm problems (amiodarone) and the widely used malaria drug chloroquine.
Chloroquine increased the progranulin level not only in experiments with mouse cells to normal, but also in cells from patients with the defective progranulin gene.
The team will now investigate whether chloroquine actually helps against progranulin-dependent frontotemporal dementia.
The study is published in the online edition of Journal of Neuroscience.